about
Ophthalmic fundus imaging: today and beyond.Chorioretinal scar growth after 810-nanometer laser treatment for retinoblastoma.Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy.Ocriplasmin: nonsurgical option for VMA and macular hole, but with potential barriers to practical use.Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion.Optical coherence tomography in asteroid hyalosis.Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization.Intravitreal triamcinolone acetonide and intraocular pressure.Time required for navigated macular laser photocoagulation treatment with the Navilas.Safety and efficacy assessment of chimeric ribozyme to proliferating cell nuclear antigen to prevent recurrence of proliferative vitreoretinopathy.Bacterial contamination of needles used for intravitreal injections: a prospective, multicenter study.A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports).Choroidal infarction following photodynamic therapy with verteporfin.Acute central serous chorioretinopathy and fundus autofluorescence.Surgical hypothesis: inner retinal fenestration as a treatment for optic disc pit maculopathy.Autofluorescence and retinal pigment epithelial atrophy after subretinal hemorrhage.The expanded spectrum of focal choroidal excavation.Persistent placoid maculopathy: a new clinical entity.Sequenced combined intravitreal triamcinolone and indocyanine green angiography-guided photodynamic therapy for retinal angiomatous proliferation.THE DURATION OF EFFECT OF CENTRIFUGE CONCENTRATED INTRAVITREAL TRIAMCINOLONE ACETONIDEBilateral Simultaneous Central Retinal Vein Occlusions in an Otherwise Healthy AdultDISAPPEARANCE OF DRUSEN AFTER RHEGMATOGENOUS RETINAL DETACHMENTDiagnostic and Therapeutic ChallengesFundus Autofluorescence in Patients with Pseudoxanthoma ElasticumMeasurement of the Actual Dose of Triamcinolone Acetonide Delivered by Common Techniques of Intravitreal InjectionPosterior capsular opacification in phacotrabeculectomy
P50
Q33199285-81050361-7273-4542-9784-2CFC20032053Q33202540-0075A18C-9E7A-4AFB-8EDE-D098443EDE34Q34472614-34E7EFB4-7B4F-42CE-96B7-211A592E6F24Q34627404-BFEEB30B-1218-46D8-A799-E39E8C5E624AQ36277128-C05B9694-0672-4A56-AF8C-B4585C4FD84BQ37408134-9D96F46D-5987-4397-BAE2-6536152CBF12Q39814702-DD59A943-611F-4B45-A3EC-7B6A03699201Q45142660-06B2B5C1-07B6-43EB-9435-75440326E1ADQ45335472-DDC3D01E-5428-41F3-B2C9-537E1301D02BQ46006684-F359F9D4-7EBF-4AC0-9CDD-AA2DB5B3DFE5Q46211373-3726FE5F-88EF-4CCD-949D-06462C3647BAQ46559657-854DCDE0-383A-413C-9321-16F68BDB6713Q46641044-E2445827-622D-4DA6-B7E8-0742B7447B96Q46844847-D7969C0E-4FA2-4AFE-9398-6D0E6F1E3DABQ46881000-2E5A9EF0-484D-49A3-9359-C656E7A3D651Q46881037-1EB40D96-9BBE-421C-A01F-40DC88779BD3Q50518713-60CAD418-29BE-4D50-95C0-75EA26603FC2Q50670829-7FF4C87D-4DA6-47AF-B511-CB08D15860ECQ50733995-74536685-6968-4AC4-A57D-9123F9FA5F09Q58655741-6EC1C427-B0C1-4032-A399-90215A245535Q58655749-EC5447E9-3D29-4F88-B39E-2CB9DBFC3CBCQ58655755-709AA359-180D-473C-B368-12653A40E1C1Q58655777-981CCDF5-6BCA-48C9-9B03-62BAC93226B8Q58655781-E533E86E-0AD3-4D33-AA29-AF6129432903Q58655785-E109202C-79DB-4F38-953C-B6E3D1D4DA7BQ58655819-D8E75281-2995-467E-A317-A3CBB99F71B8
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael Ober
@ast
Michael Ober
@en
Michael Ober
@es
Michael Ober
@nl
Michael Ober
@sl
type
label
Michael Ober
@ast
Michael Ober
@en
Michael Ober
@es
Michael Ober
@nl
Michael Ober
@sl
prefLabel
Michael Ober
@ast
Michael Ober
@en
Michael Ober
@es
Michael Ober
@nl
Michael Ober
@sl
P106
P1153
7003443963
P21
P31
P496
0000-0001-7015-0109